YM BioSciences Inc. (YMI: Quote, YM.TO) posted fourth-quarter net loss of C$6.1 million or C$0.04 per share compared to the loss of C$8.9 million or C$0.08 per share a year ago.
Revenue, generated from out-licensing, for the quarter rose to C$0.3 million from C$0.2 million in the year-ago quarter.
Analysts polled by Thomson Reuters expected the company to report a loss of C$0.05 per share on revenues of C$210 thousand for the quarter. Analysts' estimates typically exclude special items.
Dr. Nick Glover, president and chief executive officer of YM BioSciences, stated, "We made significant progress with CYT387 during Fiscal 2012, highlighted by our reporting at ASH 2011 of positive interim data that potentially differentiates our drug from other JAK inhibitors. Leveraging these data, over the last several months we conducted productive discussions with regulatory authorities in the US and Europe which have affirmed the range of options available for the pivotal program for CYT387."
Click here to receive FREE breaking news email alerts for YM Bioscience Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org